GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Karl and Nigel Sullivan take the helm at Sullivan Maritime
'Our father's lesson was that a business is only ever as good as the care you put into it.'
‘Malta’s role as hub for B2B gaming businesses continues to strengthen’ – MGA Chairman
The gaming industry continues to evolve and new business models are emerging, he said.
Ian Deguara joins Mamo TCV Advocates as a Senior Regulatory Advisor
He is the former Maltese Information and Data Protection Commissioner
Tech companies back AI support in recruitment, underscore rising importance of AI literacy
Some spoke of concerns they have over prospective employees using AI in their applications.
